Emergent BioSolutions to Participate in Investor Conferences
01 mars 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
18 févr. 2021 16h05 HE
|
Emergent BioSolutions
Reports record fourth quarter and year to date 2020 performance, in line with prior guidanceReaffirms full year 2021 forecast GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) --...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
04 févr. 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
10 janv. 2021 14h00 HE
|
Emergent BioSolutions
Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases...
Emergent BioSolutions to Participate in Investor Conferences
04 janv. 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
29 déc. 2020 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
05 nov. 2020 16h05 HE
|
Emergent BioSolutions
Reports strong third quarter and record year to date performanceUpdates full year guidance — refines revenue ranges and raises profitability ranges GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE)...
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
15 oct. 2020 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
08 oct. 2020 16h05 HE
|
Emergent BioSolutions
NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a...
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
31 août 2020 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and...